Sjögren's syndrome affects an estimated 0.5–3% of the adult population — predominantly women — making it one of the most common yet under-recognized autoimmune diseases. [1] It progressively destroys the glands that produce saliva and tears, leaving patients with severe dry mouth, dry eyes, and systemic complications. For many, conventional management with artificial tears and saliva substitutes offers limited relief without addressing the underlying autoimmune destruction.

Where conventional treatment falls short. Current standard of care — pilocarpine or cevimeline for dryness, hydroxychloroquine for systemic disease, and immunosuppressants for organ involvement — manages symptoms without halting the autoimmune attack on glandular tissue. Once salivary and lacrimal acinar tissue is destroyed, there is no approved therapy that can restore it.

The deeper problem is tissue-level. In Sjögren's, CD4+ T lymphocytes infiltrate the salivary and lacrimal glands, forming lymphocytic foci that progressively replace functional secretory epithelium. B-cell hyperactivity produces autoantibodies including anti-Ro/SSA and anti-La/SSB. [2] The result is not just dryness — it is an escalating cycle of inflammation, tissue destruction, and loss of glandular architecture that no amount of artificial moisturization can reverse.

MSC therapy targets the root cause. Rather than simply lubricating dry surfaces, mesenchymal stem cells are being studied for their ability to suppress the autoimmune lymphocytes infiltrating the glands, reduce pro-inflammatory cytokines, and secrete trophic factors that may protect and potentially regenerate damaged acinar and ductal epithelium. Early preclinical and clinical studies suggest this multimodal approach could address the immunopathology at its source. [3]

Understanding Sjögren's Syndrome: Beyond Dryness

Sjögren's syndrome is a systemic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, primarily the salivary and lacrimal glands. While sicca symptoms — dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) — define the clinical presentation, the disease often extends far beyond dryness to involve joints, lungs, kidneys, peripheral nerves, and the central nervous system.

The disease exists in two forms: primary Sjögren's syndrome, occurring in isolation, and secondary Sjögren's syndrome, accompanying another autoimmune condition such as rheumatoid arthritis or systemic lupus erythematosus. In both forms, the histological hallmark is focal lymphocytic sialadenitis — clusters of T and B cells surrounding salivary ducts, scored by the Chisholm-Mason grading system from diagnostic labial salivary gland biopsy. [4]

A defining feature and clinical concern is the elevated risk of non-Hodgkin lymphoma, which occurs in approximately 5% of patients — a 10- to 44-fold increase over the general population. Persistent parotid swelling, purpura, and low C4 complement levels are recognized predictors of lymphomagenesis, making Sjögren's far more consequential than a "dryness disease."

Key point: Sjögren's is a systemic autoimmune disease with glandular destruction at its core — but its impact spans joints, kidneys, nerves, and lymphoma risk. Any treatment that only addresses surface dryness is working at the symptom level, not the disease level.

How MSC Therapy Works in Autoimmune Glandular Disease

Mesenchymal stem cells exert therapeutic effects in Sjögren's through four interconnected mechanisms that directly address the immunopathology of the disease, without requiring the cells to engraft permanently in the damaged glands.

Immunomodulation of pathogenic lymphocytes. MSCs suppress the proliferation and activation of autoreactive CD4+ T cells — the lymphocyte population that drives sialadenitis in Sjögren's. They do this through secretion of soluble factors including indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and transforming growth factor-beta (TGF-β), which collectively shift the local immune environment from pro-inflammatory to regulatory. [5] Importantly, MSCs also inhibit B-cell maturation and antibody production, potentially reducing the anti-Ro/SSA and anti-La/SSB autoantibodies that characterize the disease.

Restoration of regulatory T-cell (Treg) populations. Sjögren's patients show quantitative and functional deficiencies in Tregs — the immune cells responsible for maintaining self-tolerance. MSC infusion has been shown to expand functional Treg populations and correct the Th17/Treg imbalance observed in active disease. [6] This is significant because Th17 cells are major drivers of glandular inflammation, and re-establishing Treg dominance represents a biologically coherent strategy for sustained immune quieting.

Paracrine trophic support for glandular epithelium. Beyond immune modulation, MSCs secrete a rich cocktail of growth factors — hepatocyte growth factor (HGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and keratinocyte growth factor (KGF) — that promote epithelial cell survival, proliferation, and repair. In salivary gland models, MSC-conditioned medium alone has been shown to protect acinar cells from apoptosis and stimulate partial functional recovery. [7]

Anti-fibrotic activity. Chronic inflammation in Sjögren's leads to progressive fibrosis of glandular tissue, replacing functional secretory units with non-functional scar. MSCs secrete matrix metalloproteinases (MMPs) and hepatocyte growth factor that can remodel fibrotic extracellular matrix, potentially preserving residual gland architecture and creating a permissive environment for epithelial regeneration.

Clinical insight: The therapeutic logic for MSCs in Sjögren's is unusually strong compared to many other autoimmune indications — not because the disease is simple, but because the mechanisms (T-cell suppression, Treg expansion, epithelial trophic support) align precisely with MSC biology. The question is not whether MSCs can do these things — they demonstrably can in vitro and in animal models — but whether they do so reliably and durably in patients with established disease.

Clinical Evidence: What the Studies Show

Clinical investigation of MSC therapy for Sjögren's syndrome is at an early stage compared to other autoimmune indications like lupus, but the existing data — predominantly from Chinese research groups — provides a coherent picture of safety and preliminary efficacy signals.

Xu et al. (2012) — First-in-human UC-MSC study. In a pioneering open-label study, 24 patients with primary Sjögren's syndrome received intravenous umbilical cord-derived MSC infusions. At 6-month follow-up, the researchers reported significant improvements in the Sjögren's Syndrome Disease Activity Index (SSDAI) and Sjögren's Syndrome Patient Reported Index (ESSPRI), with reduced salivary flow rates and lacrimal gland function in a subset of patients. No serious adverse events were attributed to the cells. [8]

Liang et al. (2017) — Longer-term follow-up. A follow-up cohort expanded to include patients treated with allogeneic UC-MSCs and followed for up to 12 months. The investigators reported sustained reductions in SSDAI scores, increased unstimulated whole salivary flow rates, and stabilization of serological markers including immunoglobulin G levels. The safety profile remained benign across the observation period.

Animal model evidence. In the NOD/ShiLtJ mouse model — which spontaneously develops Sjögren's-like autoimmune sialadenitis — MSC infusion has been shown to reduce lymphocytic infiltration of salivary glands, preserve salivary flow rates, and decrease serum autoantibody titers. Histological analysis confirmed reduced focal sialadenitis scores in treated animals. These preclinical data provide mechanistic corroboration for the clinical observations. [9]

Limitations to acknowledge: All published studies to date are small (n=24–60), open-label, and predominantly single-centre. No randomized, double-blind, placebo-controlled trial has been completed for MSC therapy in Sjögren's. The observed improvements, while encouraging, require confirmation in larger controlled studies before efficacy can be considered established. MSC therapy for Sjögren's remains investigational, not standard of care.

What Patients Might Experience: Timeline and Expectations

Based on the published protocol descriptions and clinical observations, patients receiving MSC therapy for Sjögren's typically proceed through several phases. The timeline below reflects what early studies describe — not guaranteed outcomes, but the general sequence researchers have observed.

Weeks 1–2
Infusion & Initial Response

A single intravenous infusion of allogeneic UC-MSCs, typically 1–2 × 10⁶ cells/kg. The procedure is outpatient and generally well tolerated. Some patients report transient fatigue or mild flu-like symptoms that resolve within 24–48 hours — this is a known cytokine-mediated response, not an allergic reaction.

Weeks 2–8
Early Immunomodulation

This is the window where MSCs are actively secreting immunomodulatory factors. Patients in published studies have reported the first noticeable improvements in subjective dryness during this period. Treg populations begin to expand and inflammatory cytokine levels trend downward.

Months 2–6
Functional Gains

Measurable improvements in salivary flow rate and tear production, where they occur, are typically most apparent in this window. SSDAI scores in published studies showed the steepest decline between months 3 and 6. Glandular epithelial repair, supported by MSC-derived trophic factors, may be ongoing during this period.

Months 6–12
Sustained Response Assessment

Clinicians typically assess durability at 6 and 12 months post-infusion. In the Liang cohort, patients who responded maintained their improvement through 12 months. The biological question of whether a single infusion provides durable benefit or whether maintenance infusions are needed remains an open research question.

The VELAR Approach: Laboratory Quality for Autoimmune Indications

Sjögren's syndrome presents specific clinical demands that make cell quality particularly important. Because the therapeutic goal is immunomodulation rather than tissue replacement, cell identity, purity, and potency matter enormously — MSCs that fail to meet identity criteria may lack the immunomodulatory capacity required.

Wharton's Jelly-derived UC-MSCs. VELAR uses mesenchymal stem cells sourced from Wharton's jelly of donated umbilical cord tissue — the same cell source used in the published Sjögren's studies. These perinatal MSCs are biologically young, possess strong immunomodulatory capacity, and importantly avoid the concern that autologous MSCs from an autoimmune patient may themselves be functionally compromised.

ISCT identity confirmation. Every batch is verified against the International Society for Cell & Gene Therapy criteria: plastic adherence, ≥95% expression of CD73/CD90/CD105 surface markers, ≤2% hematopoietic markers (CD34/CD45/CD11b/CD19/HLA-DR), and trilineage differentiation capacity. For an autoimmune indication, this level of characterization is non-negotiable — the therapeutic effects depend on genuine MSC biology.

GMP-compliant processing. All cell culture, expansion, and cryopreservation is performed under ISO 9001:2015 certified quality management, OECD GLP principles, and in a facility accredited by AAALAC International for animal welfare standards in associated quality testing. Multi-pathogen screening, sterility testing, and endotoxin assays are completed on every batch before release.

Frequently Asked Questions

Can stem cell therapy cure Sjögren's syndrome?

No. MSC therapy is not a cure for Sjögren's syndrome and is not positioned as one in credible medical discourse. The research aims to reduce disease activity, preserve or partially restore gland function, and improve quality of life — ambitious but realistic goals. Complete reversal of established autoimmune disease has not been demonstrated.

How much does MSC therapy for Sjögren's cost in Bangkok?

Costs vary based on cell dose, protocol complexity, and whether the treatment is part of a structured clinical program. At VELAR, treatment plans are individualized after comprehensive evaluation. Patients should consult directly for a personalized assessment rather than relying on advertised prices that may not reflect their specific clinical needs.

Is one infusion enough for Sjögren's?

This is an open question. Published studies have used single-infusion protocols with follow-up out to 12 months, and some patients showed sustained benefit. However, whether maintenance infusions at 6–12 month intervals provide additional or prolonged benefit has not been systematically studied. Treatment decisions are individualized based on response.

Are there risks specific to Sjögren's patients?

The general safety profile of allogeneic UC-MSC infusion is favorable, with no serious adverse events attributed to the cells in published Sjögren's studies. However, Sjögren's patients carry elevated lymphoma risk, and any patient considering an investigational therapy should have a thorough pre-treatment evaluation including lymphoma screening. All patients should discuss their individual risk profile with the treating physician.

What makes Bangkok a destination for Sjögren's stem cell treatment?

Bangkok has emerged as a hub for regenerative medicine in Asia due to Thailand's progressive regulatory framework for cell therapy, internationally trained physicians, GMP-compliant laboratory infrastructure, and significantly lower treatment costs compared to Western countries. VELAR Center operates within this ecosystem with full laboratory accreditation and transparent clinical practices.

How do I know if I am a candidate?

Candidate selection is based on diagnosis confirmation (typically via positive anti-Ro/SSA and/or anti-La/SSB antibodies plus labial salivary gland biopsy), disease activity level, prior treatment history, and overall health status. Patients with active systemic complications require careful multidisciplinary evaluation. A comprehensive pre-treatment consultation with medical history review is the first step.

Limitations and Honest Assessment

MSC therapy for Sjögren's syndrome is a field with strong preclinical rationale and encouraging early clinical signals, but it remains investigational. The published evidence is limited to small open-label studies and animal models. No randomized controlled trial has been completed; no regulatory agency has approved MSCs for Sjögren's; and the durability of any benefit beyond 12 months is unknown.

Patients considering this therapy should understand that they are making a decision based on early evidence and biological plausibility — not on proven efficacy. The responsible clinical posture is to present MSC therapy as an option within a comprehensive management plan, not as a replacement for conventional rheumatologic care. At VELAR, we believe transparency about these limitations is not a weakness — it is how patients make genuinely informed choices.

References

  1. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. 2015;74(11):1983-1989. doi:10.1136/annrheumdis-2014-205375 ↩
  2. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nature Reviews Rheumatology. 2013;9(9):544-556. doi:10.1038/nrrheum.2013.110 ↩
  3. Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Research & Therapy. 2014;16(2):R79. doi:10.1186/ar4520 ↩
  4. Fisher BA, Jonsson R, Daniels T, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 2017;76(7):1161-1168. doi:10.1136/annrheumdis-2016-210448 ↩
  5. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  6. Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Research & Therapy. 2013;4(3):65. doi:10.1186/scrt216 ↩
  7. Pringle S, Maimets M, van der Zwaag M, et al. Human salivary gland stem cells functionally restore radiation damaged salivary glands. Stem Cells. 2016;34(3):640-652. doi:10.1002/stem.2278 ↩
  8. Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren's syndrome. Blood. 2012;120(15):3142-3151. doi:10.1182/blood-2011-11-391144 ↩
  9. Khalili S, Liu Y, Kornete M, et al. Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren's-like disease. PLoS ONE. 2012;7(6):e38615. doi:10.1371/journal.pone.0038615 ↩
  10. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  11. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjögren syndrome. BMJ. 2012;344:e3821. doi:10.1136/bmj.e3821 ↩
  12. Munir H, McGettrick HM. Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells and Development. 2015;24(18):2091-2100. doi:10.1089/scd.2015.0008 ↩
  13. Liang J, Zhang H, Hua B, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory Sjögren's syndrome. Journal of Translational Medicine. 2017;15:154. doi:10.1186/s12967-017-1250-0 ↩
  14. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  15. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩